Gender-Associated Outcomes Following Percutaneous Coronary Intervention With a Third-Generation, Ultrathin-Strut Drug-Eluting Stent: A Real-World, Single-Center Experience

Front Cardiovasc Med

3 March Mar 2022 2 months ago
  • Gili S, Galli S, Teruzzi G, Santagostino Baldi G, Ravagnani P, Fabbiocchi F, Bartorelli A, Montorsi P, Trabattoni D.

In recent years, the new third-generation ultrathin bioresorbable-polymer sirolimus-eluting stent (BP-SES), characterized by some of the thinnest struts among commercially available devices (60-80 μm) and an amorphous silicon carbide coating, has been introduced for the treatment of coronary artery disease (CAD). The present study aimed to assess different clinical outcomes and safety of this drug-eluting stent in male and female patients in a real-world setting.

Reference

Gender-Associated Outcomes Following Percutaneous Coronary Intervention With a Third-Generation, Ultrathin-Strut Drug-Eluting Stent: A Real-World, Single-Center Experience.
Gili S, Galli S, Teruzzi G, Santagostino Baldi G, Ravagnani P, Fabbiocchi F, Bartorelli A, Montorsi P, Trabattoni D. Front Cardiovasc Med. 2022 Feb 11;8:796604.

Go to PubMed